
Synthomics
Synthomics is committed to driving life sciences innovation at its most basic level by dramatically improving upon DNA and RNA synthesis.
Date | Investors | Amount | Round |
---|---|---|---|
N/A | €0.0 | round | |
investor | €0.0 | round | |
N/A | Seed | ||
Total Funding | 000k |
Related Content
Synthomics, founded by Stanford researchers, specializes in ultra low cost, high throughput oligo synthesis technology. The company aims to revolutionize DNA synthesis by deploying push button synthesizers directly with end users. Synthomics serves biotechnology firms, research institutions, and pharmaceutical companies, operating primarily in the synthetic biology and genomics markets. Its business model focuses on selling the Green Machine synthesizer, which significantly reduces reagent consumption and costs by 20 times through innovations in rapid motion control, miniaturized consumables, and microfluidics. Revenue is generated through the sale of these synthesizers and associated consumables.
Keywords: DNA synthesis, biotechnology, genomics, push button synthesizers, Stanford researchers, reagent reduction, cost efficiency, synthetic biology, microfluidics, high throughput.